SMAD2 and neoplasm: Emergent research illuminates that LIF, an immunomodulatory signaling molecule, might operate as a critical effector downstream of the TGF-β/Smad2/3 pathway, furnishing a pivotal axis in tumor immunoresponsivity and potentially metastasis [27].